168 related articles for article (PubMed ID: 14573389)
1. Molecular mechanisms of inhibition of nicotinic acetylcholine receptors by tricyclic antidepressants.
Gumilar F; Arias HR; Spitzmaul G; Bouzat C
Neuropharmacology; 2003 Dec; 45(7):964-76. PubMed ID: 14573389
[TBL] [Abstract][Full Text] [Related]
2. Tricyclic antidepressants inhibit homomeric Cys-loop receptors by acting at different conformational states.
Gumilar F; Bouzat C
Eur J Pharmacol; 2008 Apr; 584(1):30-9. PubMed ID: 18314100
[TBL] [Abstract][Full Text] [Related]
3. (-)-Reboxetine inhibits muscle nicotinic acetylcholine receptors by interacting with luminal and non-luminal sites.
Arias HR; Ortells MO; Feuerbach D
Neurochem Int; 2013 Nov; 63(5):423-31. PubMed ID: 23917086
[TBL] [Abstract][Full Text] [Related]
4. Noncompetitive antagonist binding sites in the torpedo nicotinic acetylcholine receptor ion channel. Structure-activity relationship studies using adamantane derivatives.
Arias HR; Trudell JR; Bayer EZ; Hester B; McCardy EA; Blanton MP
Biochemistry; 2003 Jun; 42(24):7358-70. PubMed ID: 12809491
[TBL] [Abstract][Full Text] [Related]
5. Different interaction between tricyclic antidepressants and mecamylamine with the human alpha3beta4 nicotinic acetylcholine receptor ion channel.
Arias HR; Targowska-Duda KM; Feuerbach D; Sullivan CJ; Maciejewski R; Jozwiak K
Neurochem Int; 2010 Mar; 56(4):642-9. PubMed ID: 20117161
[TBL] [Abstract][Full Text] [Related]
6. Inhibitory mechanisms and binding site location for serotonin selective reuptake inhibitors on nicotinic acetylcholine receptors.
Arias HR; Feuerbach D; Bhumireddy P; Ortells MO
Int J Biochem Cell Biol; 2010 May; 42(5):712-24. PubMed ID: 20079457
[TBL] [Abstract][Full Text] [Related]
7. Tricyclic antidepressants and mecamylamine bind to different sites in the human alpha4beta2 nicotinic receptor ion channel.
Arias HR; Rosenberg A; Targowska-Duda KM; Feuerbach D; Jozwiak K; Moaddel R; Wainer IW
Int J Biochem Cell Biol; 2010 Jun; 42(6):1007-18. PubMed ID: 20223294
[TBL] [Abstract][Full Text] [Related]
8. Tricyclic antidepressants inhibit hippocampal α7* and α9α10 nicotinic acetylcholine receptors by different mechanisms.
Arias HR; Vázquez-Gómez E; Hernández-Abrego A; Gallino S; Feuerbach D; Ortells MO; Elgoyhen AB; García-Colunga J
Int J Biochem Cell Biol; 2018 Jul; 100():1-10. PubMed ID: 29704625
[TBL] [Abstract][Full Text] [Related]
9. Molecular mechanisms and binding site location for the noncompetitive antagonist crystal violet on nicotinic acetylcholine receptors.
Arias HR; Bhumireddy P; Spitzmaul G; Trudell JR; Bouzat C
Biochemistry; 2006 Feb; 45(7):2014-26. PubMed ID: 16475790
[TBL] [Abstract][Full Text] [Related]
10. Characterization of interaction of 3,4,5-trimethoxybenzoic acid 8-(diethylamino)octyl ester with Torpedo californica nicotinic acetylcholine receptor and 5-hydroxytryptamine3 receptor.
Sun H; McCardy EA; Machu TK; Blanton MP
J Pharmacol Exp Ther; 1999 Jul; 290(1):129-35. PubMed ID: 10381768
[TBL] [Abstract][Full Text] [Related]
11. The local anaesthetics proadifen and adiphenine inhibit nicotinic receptors by different molecular mechanisms.
Spitzmaul G; Gumilar F; Dilger JP; Bouzat C
Br J Pharmacol; 2009 Jul; 157(5):804-17. PubMed ID: 19422391
[TBL] [Abstract][Full Text] [Related]
12. Differentiation of the open and closed states of the ionic channels of nicotinic acetylcholine receptors by tricyclic antidepressants.
Schofield GG; Witkop B; Warnick JE; Albuquerque EX
Proc Natl Acad Sci U S A; 1981 Aug; 78(8):5240-4. PubMed ID: 6272297
[TBL] [Abstract][Full Text] [Related]
13. Interaction of bupropion with muscle-type nicotinic acetylcholine receptors in different conformational states.
Arias HR; Gumilar F; Rosenberg A; Targowska-Duda KM; Feuerbach D; Jozwiak K; Moaddel R; Wainer IW; Bouzat C
Biochemistry; 2009 Jun; 48(21):4506-18. PubMed ID: 19334677
[TBL] [Abstract][Full Text] [Related]
14. Determinants of phencyclidine potency on the nicotinic acetylcholine receptors from muscle and electric organ.
Eterović VA; Lu R; Eakin AE; Rodríguez AD; Ferchmin PA
Cell Mol Neurobiol; 1999 Dec; 19(6):745-57. PubMed ID: 10456235
[TBL] [Abstract][Full Text] [Related]
15. The steroid promegestone is a noncompetitive antagonist of the Torpedo nicotinic acetylcholine receptor that interacts with the lipid-protein interface.
Blanton MP; Xie Y; Dangott LJ; Cohen JB
Mol Pharmacol; 1999 Feb; 55(2):269-78. PubMed ID: 9927618
[TBL] [Abstract][Full Text] [Related]
16. The acetylcholinesterase inhibitor BW284c51 is a potent blocker of Torpedo nicotinic AchRs incorporated into the Xenopus oocyte membrane.
Olivera-Bravo S; Ivorra I; Morales A
Br J Pharmacol; 2005 Jan; 144(1):88-97. PubMed ID: 15644872
[TBL] [Abstract][Full Text] [Related]
17. 5-Doxylstearate-induced displacement of phencyclidine from its low-affinity binding sites on the nicotinic acetylcholine receptor.
Arias HR
Arch Biochem Biophys; 1999 Nov; 371(1):89-97. PubMed ID: 10525293
[TBL] [Abstract][Full Text] [Related]
18. Antagonism of nicotinic acetylcholine receptors by inhibitors of monoamine uptake.
López-Valdés HE; García-Colunga J
Mol Psychiatry; 2001 Sep; 6(5):511-9. PubMed ID: 11526465
[TBL] [Abstract][Full Text] [Related]
19. Interactions of tricyclic antidepressants with a synaptic ion channel.
Aronstam RS
Life Sci; 1981 Jan; 28(1):59-64. PubMed ID: 6261057
[No Abstract] [Full Text] [Related]
20. Blockage of mouse muscle nicotinic receptors by serotonergic compounds.
García-Colunga J; Miledi R
Exp Physiol; 1999 Sep; 84(5):847-64. PubMed ID: 10502654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
